Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Insight - Scouting around at Merck

This article was originally published in Scrip

Executive Summary

In the past six months, Merck & Cohas signed at least seven external licensing deals with a variety of companies to gain access to cutting-edge research and clinical candidates. The deals cover a broad spectrum: for example, Merck licensed out two preclinical cancer targets in a risk-sharing deal with Nicholas Piramal of India and it is collaborating with Celera to gain access to cancer targets discovered by the US firm's proteomics technology. It also signed a potential $700 million deal with Addex Pharmaceuticals to gain exclusive rights to the Swiss firm's preclinical schizophrenia candidate ADX63365.

Topics

Related Companies

UsernamePublicRestriction

Register

SC007198

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel